Skip to main content
CMPX logo

CMPX · Compass Therapeutics, Inc.

Track CMPX — free
$0.67 -0.01 (-1.25%)
Market Cap
$122.19M
Shares
180.09M
Volume · Nov 19 1.68M Avg daily vol (3M) 3.86M

Price & Indicators

 

Key stats

Close
$0.68
Open
$0.62
Day range
$0.60–0.68
52-week closing range
$0.61–6.69
Average volume, 30 days
2.4M
Short interest
40.8M · 22.6% of shares · 18.9 days
Short volume, last session
41%
Last earnings
May 20, 2026
Latest filing
10-Q · Nov 9
Price history
Apr 2021 to Nov 2026

Up next

Nov 26, 2026 Est · unconfirmed · in 1 wks

Latest documents

2026
Nov 11
Investor event
Tevesimig FDA engagement precedes BLA; cash runs into 2028

Compass Therapeutics is re-engaging FDA on Tevesimig for biliary tract cancer and targets a BLA submission in the first half of the coming year. The company reported $163 million in cash, well into 2028.

4 source passages
So, for those of you who don't know, Compass, we're located in Boston. Our lead program, Tevesimig, a couple of weeks ago, we presented data from a randomized trial at ESMO, and we simultaneously published all that data in the Journal of Clinical Oncology. on October 24th, and we're sort of in the middle of re-engaging with FDA right now in order to have a conversation about a path forward to get this drug approved for the treatment of patients with biliary tract cancer. So I think, I think absent that, we would move forward with a BLA submission in the first half of the coming year. Financials two days ago, $163 million, you know, cash well into 2028. Open the document at this passage
Nov 9
Investor event
Tevesimig showed strong efficacy, but FDA path remains unresolved

Compass Therapeutics is pursuing FDA engagement after Tevesimig more than tripled the overall response rate and reported a 0.44 progression-free survival hazard ratio, but overall survival did not differ in intent-to-treat analysis.

4 source passages
All right, so welcome to this next fireside chat with Compass Therapeutics. The drug clearly works, right? There's just no question about it. So we more than tripled the overall response rate. Progression-free survival had a hazard ratio of 0.44, a hazard ratio on PFS that you don't see every day. The overall survival in the intent-to-treat analysis was not different. We're working to re-engage with the FDA. Open the document at this passage
Nov 9
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Cash runway expected into 2028

Compass Therapeutics held $163 million in cash, cash equivalents and marketable securities as of September 30, 2026 and expects those resources to fund operating expenses and capital expenditure requirements into 2028.

Net loss $27.17M
Read from the first part of this long document
2 source passages
As of September 30, 2026, the total of cash, cash equivalents and marketable securities was $163 million. The Company expects such cash resources will fund operating expenses and capital expenditure requirements into 2028. Open the document at this passage
Nov 9
Current report 8-K
Tovecimig BLA Preparation Advances Despite FDA Survival-Study Request

Compass Therapeutics is preparing a tovecimig BLA for biliary tract cancer despite FDA's recommendation for an additional survival-benefit study. It reported a $27.2 million quarterly net loss, with $163 million in cash and marketable securities expected to fund operations into 2028.

Financial results
5 source passages
Compass is advancing preparations for a BLA submission for tovecimig in patients with BTC and plans to further engage with the FDA. In September 2026, the Company disclosed that the FDA recommended an additional study demonstrating a survival benefit before submission of a BLA. Net loss for the quarter ended September 30, 2026, was $27.2 million or $0.15 per common share, compared to $14.3 million or $0.08 per common share for the same period in 2025. As of September 30, 2026, cash and marketable securities were $163 million as compared to $209 million as of December 31, 2025. Based on current operating plans, the anticipated cash runway is into 2028. Open the document at this passage
Sep 22
Current report 8-K
Regulation FD disclosure

On September 22, 2026, Compass Therapeutics said the FDA recommended a survival-benefit trial before a tovecimig BLA submission for previously treated, advanced biliary tract cancer; the company disputes that need and plans further FDA engagement.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$86.36M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-50.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$163.06M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+29.4%
Year over year · more shares
Price change (1Y)
-86.2%
Trailing year
Short interest
22.6%
Latest settlement · 18.9 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.72
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −76%
below
Price vs 50-day avg −33%
below
RSI (14) 36
neutral
MACD trend Positive
52-week position 1%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −15%
trailing
6-month return −69%
trailing
YTD return −87%
this year
Relative strength −64%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $1 › 200d $3 — 200d above 50d
Institutional flow Distributing
-19% holders QoQ · +23 funds added
Insider flow Accumulating
Net +$27.2K over 90 days · 0% sells
Short interest Falling
22.65% of shares out · ▼ -2.5% MoM · 18.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
176 holders — mid 3-yr range
Squeeze score 67
elevated · 0–100
Fundamentals
Weak
Revenue growth −100%
Y/Y
Free cash flow $-49.2M
Balance sheet $30.6M
net cash
Quant / Vol
risk profile
Very High
Volatility 98%
annualized · 1-yr
Max drawdown −91%
past year
ATR 10.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−76% Bearish
Price vs 50-day avg
−33% Bearish
RSI (14)
36 Neutral
MACD trend
Positive Bullish
52-week position
1% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $1 › 200d $3 — 200d above 50d
Institutional flow Distributing
-19% holders QoQ · +23 funds added
Insider flow Accumulating
Net +$27.2K over 90 days · 0% sells
Short interest Falling
22.65% of shares out · ▼ -2.5% MoM · 18.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
176 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $1 · 1% Range high $7
vs 200-day avg -76% vs 50-day avg -33%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
cash and marketable securities $163M end of Q3 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CMPX
Compass Therapeutics, Inc.
this stock
$122.19M -87.4% -100.0% — 22.6%
VRTX
Vertex Pharmaceuticals Inc
$132.01B +14.8% +46.2% 33.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.52B +19.6% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$80.65B +575.9% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.36B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
176
% held
89.2%
Net QoQ
-5.1M sh
Top holder
TANG CAPITAL MANAGEMENT L…
Held Float
View
Held by Funds
Fund positions
143
View
Short & Settlement
Short Interest Falling
Shares short
40.8M
Days to cover
18.9d
Change
-1.1M sh
View
Short Volume
Short vol %
41%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
31.3K
Value
$23.8K
As of
Oct 29, 2026
View
Off-Exchange
Off-exchange %
61.8%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$27.2K
Buyers / Sellers
1 / 0
Buyers Sellers
View
Financials
Financials
Net income (FY)
$-66.5M
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 11, 2026
This year
20

Compass Therapeutics is re-engaging FDA on Tevesimig for biliary tract cancer and targets a BLA submission in the first half of the coming year. The company reported $163 million in cash, well into 2028.

View
Proposed Sales
Value
$5.7M
Shares
3.6M
Filed
Apr 9, 2025
View
Exempt Offerings
Offering
$70.0M
Filed
Jul 1, 2020
View
Earnings & Events
Webcasts
Last webcast
Nov 11, 2026
View
Investor Relations
Latest news
Compass Therapeutics Reports 2026…
Published
Nov 9, 2026
View

Performance

5D 20D 120D MTD YTD
CMPX -17.3% -15.4% -69.4% -13.7% -87.4%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -11.8% -9.1% -63.8% -8.5% -92.3%
Key facts CIK 1738021 CUSIP 20454B104 13F (30d) 187 filings 169 filers Visit website Investor relations